Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Repros Therapeutics Inc.

Latest From Repros Therapeutics Inc.

Seven Green Lights From EU’s CHMP, Including Drugs For Hemophilia, Diabetes, Alpha Mannosidosis And Hyperkalemia

The European Medicines Agency’s CHMP has OKd seven new products, including drugs for hemophilia A, diabetes, alpha mannosidosis, hyperkalemia and herpes zoster. But it again rejected Santhera’s filing for Raxone in the new indication of Duchenne muscular dystrophy, and also turned down Repros’ Encyzix for hypogonadism.

Approvals Advisory Committees

Roche’s Hemlibra Looking For CHMP Green Light, Crunch Time for Santhera DMD Hopeful

The first meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London, with a number of new drugs up for a marketing authorization recommendation.

Europe Approvals

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products

Draft is intended to inform development of non-testosterone products such as aromatase inhibitors or estrogen receptor agonists.

Drug Approval Standards Gynecology & Urology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Metabolic Disorders
  • Alias(es)
  • Zonagen Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Repros Therapeutics Inc.
  • Senior Management
  • Larry Dillaha, MD, Pres. & CEO
    Katherine A Anderson, CFO
  • Contact Info
  • Repros Therapeutics Inc.
    Phone: (281) 719-3400
    2408 Timberloch Pl.
    Ste. B-1
    The Woodlands, TX 77380